- Home
- CNXN vs AKRO Comparison
CNXN vs AKRO Comparison
Compare CNXN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNXN
- AKRO
- Stock Information
- Founded
- CNXN 1982
- AKRO 2017
- Country
- CNXN United States
- AKRO United States
- Employees
- CNXN N/A
- AKRO N/A
- Industry
- CNXN Catalog/Specialty Distribution
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CNXN Consumer Discretionary
- AKRO Health Care
- Exchange
- CNXN Nasdaq
- AKRO Nasdaq
- Market Cap
- CNXN 1.9B
- AKRO 2.2B
- IPO Year
- CNXN 1998
- AKRO 2019
- Fundamental
- Price
- CNXN $69.00
- AKRO $29.34
- Analyst Decision
- CNXN
- AKRO Strong Buy
- Analyst Count
- CNXN 0
- AKRO 8
- Target Price
- CNXN N/A
- AKRO $46.83
- AVG Volume (30 Days)
- CNXN 81.1K
- AKRO 610.0K
- Earning Date
- CNXN 02-12-2025
- AKRO 11-08-2024
- Dividend Yield
- CNXN 0.58%
- AKRO N/A
- EPS Growth
- CNXN 14.84
- AKRO N/A
- EPS
- CNXN 3.40
- AKRO N/A
- Revenue
- CNXN $2,789,687,000.00
- AKRO N/A
- Revenue This Year
- CNXN $0.71
- AKRO N/A
- Revenue Next Year
- CNXN $5.15
- AKRO N/A
- P/E Ratio
- CNXN $20.30
- AKRO N/A
- Revenue Growth
- CNXN N/A
- AKRO N/A
- 52 Week Low
- CNXN $57.47
- AKRO $15.32
- 52 Week High
- CNXN $77.19
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- CNXN 37.90
- AKRO 45.72
- Support Level
- CNXN $70.07
- AKRO $27.35
- Resistance Level
- CNXN $75.08
- AKRO $31.41
- Average True Range (ATR)
- CNXN 1.94
- AKRO 1.56
- MACD
- CNXN -0.53
- AKRO -0.21
- Stochastic Oscillator
- CNXN 2.22
- AKRO 42.16
About CNXN PC Connection Inc.
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.